News
The latest news from around the Biomedical Research Centre, The Royal Marsden and The Institute of Cancer Research, London.
- 23 October 2018 “Landmark results” in key ovarian cancer research
Results from a Phase III trial have demonstrated that lynparza (olaparib) therapy could cut the risk of disease progression or death by 70% in
- 23 October 2018 Women may experience more side effects than men during gastric cancer chemotherapy
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG cancer): a pooled analysis of 4 randomised trials
- 09 July 2018 Pathway to Independence programme open for applications
We are pleased to invite applications for our flagship capacity building programme.
- 11 June 2018 Applications open for BRC post-doctoral support
We are pleased to again offer time-limited funding to support high calibre individuals who have clear long term plans to pursue a clinical aca
- 10 May 2018 Applications open for Pan London Collaborative Research Fellows
We are offering exciting opportunities for medical and non-medical research fellows to undertake a research project.
- 09 August 2017 New tests select patients who could live for nearly a year longer on targeted bowel cancer drug
Giving patients with bowel cancer an MRI scan and a blood test could pick out those who would benefit from a targeted cancer treatment, a new
- 03 July 2017 MR Linac in place
The MR Linac machine is now in place at The Royal Marsden's site in Sutton
- 19 June 2017 New blood test opens door to precision treatment for prostate cancer
Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs
- 19 May 2017 International Clinical Trials Day highlights importance of research
Staff at The Royal Marsden are celebrating International Clinical Trials Day and showcasing the importance of research and clinical trials.
- 04 May 2017 New blood test predicts who will benefit from targeted prostate cancer treatments
A new blood test could predict which men with advanced prostate cancer will respond to new targeted treatments for the disease